Physician profile
John Robert Sebok
NPI 1295754943
$1,095.96
in general payments reported to CMS, 2019-2025
19 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.37 · 2020: $37.52 · 2021: $94.82 · 2022: $202 · 2023: $226 · 2024: $283 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $154.24 | 2024-2025 | Briviact, Fintepla |
| Eisai INC. | $140.46 | 2021-2024 | |
| Abbvie INC. | $122.99 | 2023-2025 | Ubrelvy, Qulipta |
| Biodelivery Sciences International, INC. | $100.77 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $96.33 | 2024-2025 | Nuplazid |
| Sk Life Science, INC. | $82.65 | 2023-2024 | |
| Harmony Biosciences LLC | $66.66 | 2023-2025 | Wakix |
| Csl Behring | $61.00 | 2022 | |
| Medtronic, INC. | $37.80 | 2023 | Intellis Adaptivestim |
| Argenx US, INC. | $33.90 | 2023 | Vyvgart |
| Amneal Pharmaceuticals LLC | $31.63 | 2024-2025 | Rytary, Crexont |
| Averitas Pharma INC. | $27.26 | 2023 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $23.52 | 2024 | Nuedexta |
| Teva Pharmaceuticals USA, INC. | $23.34 | 2019 | |
| Novo Nordisk INC | $22.04 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $21.39 | 2025 | Tysabri, Vumerity |
| Amgen INC. | $18.06 | 2022 | |
| Lilly USA, LLC | $16.31 | 2022 | |
| Grifols USA, LLC | $15.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sebok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.